FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056361036> ?p ?o ?g. }

• W2056361036 abstract "Ustekinumab and briakinumab, monoclonal antibodies to the shared p40 subunit of interleukin (IL)-12 and IL-23, have shown efficacy in treating chronic plaque psoriasis (CPP). Preliminary reports of major adverse cardiovascular events (MACEs) in psoriasis patients receiving anti-IL-12/23 agents have prompted concern.To evaluate a possible association between biologic therapies for CPP and MACEs via meta-analysis.Randomized controlled trials (RCTs) of anti-IL-12/23 (ustekinumab and briakinumab) agents and anti-tumor necrosis factor α (TNF-α) agents (adalimumab, etanercept, and infliximab) used in treating CPP were reviewed using the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Ovid MEDLINE from database inception to May 2011. The results of registered nonpublished completed studies were procured through abstract publications or poster presentations.Randomized, placebo-controlled, double-blind, monotherapy studies (with safety outcome data for MACE) of IL-12/23 antibodies and anti-TNF-α agents in adults. Studies of psoriatic arthritis were excluded.Two investigators independently searched data while 6 investigators reviewed the abstracted data.A total of 22 RCTs comprising 10 183 patients met the predefined inclusion criteria. The primary outcome measure was MACE, a composite end point of myocardial infarction, cerebrovascular accident, or cardiovascular death during the placebo-controlled phase of treatment in patients receiving at least 1 dose of study agent or placebo. Absolute risk differences were used as an effect measure. There was no evidence of statistical heterogeneity across the studies using the I(2) statistic (I(2) = 0), allowing for combination of trial results using the Mantel-Haenszel fixed-effects method. During the placebo-controlled phases of the anti-IL-12/23 studies, 10 of 3179 patients receiving anti-IL-12/23 therapies experienced MACEs compared with zero events in 1474 patients receiving placebo (Mantel-Haenszel risk difference, 0.012 events/person-year; 95% confidence interval [CI], -0.001 to 0.026; P =.12). In the anti-TNF-α trials, only 1 of 3858 patients receiving anti-TNF-α agents experienced a MACE compared with 1 of 1812 patients receiving placebo (Mantel-Haenszel risk difference, -0.0005 events/person-year; 95% CI, -0.010 to 0.009; P = .94).Compared with placebo, there was no significant difference in the rate of MACEs observed in patients receiving anti-IL-12/IL-23 antibodies or anti-TNF-α treatments. This study may have been underpowered to identify a significant difference." @default.
• W2056361036 created "2016-06-24" @default.
• W2056361036 creator A5008142348 @default.
• W2056361036 creator A5014063407 @default.
• W2056361036 creator A5030564505 @default.
• W2056361036 creator A5037836846 @default.
• W2056361036 creator A5041009132 @default.
• W2056361036 creator A5050010339 @default.
• W2056361036 creator A5051212717 @default.
• W2056361036 creator A5053207979 @default.
• W2056361036 creator A5055048278 @default.
• W2056361036 creator A5059337854 @default.
• W2056361036 creator A5061849637 @default.
• W2056361036 creator A5075798284 @default.
• W2056361036 creator A5080337749 @default.
• W2056361036 creator A5091485944 @default.
• W2056361036 date "2011-08-24" @default.
• W2056361036 modified "2023-10-17" @default.
• W2056361036 title "Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events" @default.
• W2056361036 cites W1517017118 @default.
• W2056361036 cites W1555461460 @default.
• W2056361036 cites W1571088251 @default.
• W2056361036 cites W1832679015 @default.
• W2056361036 cites W1894367943 @default.
• W2056361036 cites W1909033269 @default.
• W2056361036 cites W1965873026 @default.
• W2056361036 cites W1975463338 @default.
• W2056361036 cites W1984804536 @default.
• W2056361036 cites W1985408199 @default.
• W2056361036 cites W1996642272 @default.
• W2056361036 cites W2005176759 @default.
• W2056361036 cites W2008716526 @default.
• W2056361036 cites W2013361256 @default.
• W2056361036 cites W2022665587 @default.
• W2056361036 cites W2023733075 @default.
• W2056361036 cites W2024546767 @default.
• W2056361036 cites W2025081559 @default.
• W2056361036 cites W2030348118 @default.
• W2056361036 cites W2037062908 @default.
• W2056361036 cites W2050442819 @default.
• W2056361036 cites W2056468769 @default.
• W2056361036 cites W2063627867 @default.
• W2056361036 cites W2071343804 @default.
• W2056361036 cites W2073924006 @default.
• W2056361036 cites W2077859166 @default.
• W2056361036 cites W2087722290 @default.
• W2056361036 cites W2088155036 @default.
• W2056361036 cites W2091442391 @default.
• W2056361036 cites W2102774054 @default.
• W2056361036 cites W2104662516 @default.
• W2056361036 cites W2116956799 @default.
• W2056361036 cites W2118794261 @default.
• W2056361036 cites W2122148738 @default.
• W2056361036 cites W2125435699 @default.
• W2056361036 cites W2135393211 @default.
• W2056361036 cites W2139562487 @default.
• W2056361036 cites W2143786724 @default.
• W2056361036 cites W2145699341 @default.
• W2056361036 cites W2146843653 @default.
• W2056361036 cites W2146901298 @default.
• W2056361036 cites W2149566497 @default.
• W2056361036 cites W2156098321 @default.
• W2056361036 cites W2158131645 @default.
• W2056361036 cites W2164533070 @default.
• W2056361036 cites W2167962196 @default.
• W2056361036 cites W2168911501 @default.
• W2056361036 cites W2172257129 @default.
• W2056361036 cites W2991792334 @default.
• W2056361036 doi "https://doi.org/10.1001/jama.2011.1211" @default.
• W2056361036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21862748" @default.
• W2056361036 hasPublicationYear "2011" @default.
• W2056361036 type Work @default.
• W2056361036 sameAs 2056361036 @default.
• W2056361036 citedByCount "213" @default.
• W2056361036 countsByYear W20563610362012 @default.
• W2056361036 countsByYear W20563610362013 @default.
• W2056361036 countsByYear W20563610362014 @default.
• W2056361036 countsByYear W20563610362015 @default.
• W2056361036 countsByYear W20563610362016 @default.
• W2056361036 countsByYear W20563610362017 @default.
• W2056361036 countsByYear W20563610362018 @default.
• W2056361036 countsByYear W20563610362019 @default.
• W2056361036 countsByYear W20563610362020 @default.
• W2056361036 countsByYear W20563610362021 @default.
• W2056361036 countsByYear W20563610362022 @default.
• W2056361036 countsByYear W20563610362023 @default.
• W2056361036 crossrefType "journal-article" @default.
• W2056361036 hasAuthorship W2056361036A5008142348 @default.
• W2056361036 hasAuthorship W2056361036A5014063407 @default.
• W2056361036 hasAuthorship W2056361036A5030564505 @default.
• W2056361036 hasAuthorship W2056361036A5037836846 @default.
• W2056361036 hasAuthorship W2056361036A5041009132 @default.
• W2056361036 hasAuthorship W2056361036A5050010339 @default.
• W2056361036 hasAuthorship W2056361036A5051212717 @default.
• W2056361036 hasAuthorship W2056361036A5053207979 @default.
• W2056361036 hasAuthorship W2056361036A5055048278 @default.
• W2056361036 hasAuthorship W2056361036A5059337854 @default.
• W2056361036 hasAuthorship W2056361036A5061849637 @default.
• W2056361036 hasAuthorship W2056361036A5075798284 @default.
• W2056361036 hasAuthorship W2056361036A5080337749 @default.

• next